A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer

N/ACompletedNCT02761616

Hoffmann-La Roche76 enrolled

Overview

This is a retrospective, and observational cohort study to determine the proportion of breast cancer first relapses, that are biopsied. The duration of the study will be approximately 24 months.

Study Type

OBSERVATIONAL

Enrollment

76

Conditions

Interventions

eBC treated participantsOTHER

No intervention administered in this retrospective observational study.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants with histologically confirmed breast cancer treated for early breast cancer (eBC) with first metastatic relapse disease in the period from January 1, 2014 and December 31, 2015 Exclusion Criteria: Not Applicable

Locations (4)

Cemic; Oncologia Clinica

Buenos Aires, Argentina

Hospital de Morón

Morón, Argentina

CENICLAR

Rosario, Argentina

Centro Medico San Roque

San Miguel de Tucumán, Argentina

Outcomes

Primary Outcomes

Percentage of biopsied participants with metastatic relapse

Time frame: Approximately up to 24 months

Secondary Outcomes

Percentage of non-biopsied participants at first relapse according to different reasons for not performing a biopsy of the metastasis

Time frame: Approximately up to 24 months

Percentage of biopsied and non-biopsied participants at first relapse metastatic breast cancer (mBC) for each metastatic site

Time frame: Approximately up to 24 months

Percentage of biopsied participants at first relapse mBC according to each biopsy method

Time frame: Approximately up to 24 months

Percentage of biopsied and non- biopsied participants at first relapse mBC for each molecular profile of primary tumor

Time frame: Approximately up to 24 months

Percentage of biopsied participants at first relapse mBC for each molecular profile of biopsied metastases

Time frame: Approximately up to 24 months

Percentage of biopsied participants at first relapse mBC with same and different molecular profiles between primary tumor and metastasis for each molecular profile

Time frame: Approximately up to 24 months

Time to relapse

Time frame: Approximately up to 24 months

Percentage of participants with type of first line therapy selected for metastatic disease

Time frame: Approximately up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT02761616 - A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer | Crick | Crick